Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31094793,peak concentrations,"The pharmacokinetic profile of levobupivacaine was comparable in the 2 groups: the mean total and free levobupivacaine peak concentrations were 379 ± 248 and 3.95 ± 3.16 ng·mL, respectively, occurring 22.5 ± 11 minutes after injection.",Transversus Abdominal Plane Block in Children: Efficacy and Safety: A Randomized Clinical Study and Pharmacokinetic Profile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094793/),ml·ng,379,14599,DB01002,Levobupivacaine
,31094793,peak concentrations,"The pharmacokinetic profile of levobupivacaine was comparable in the 2 groups: the mean total and free levobupivacaine peak concentrations were 379 ± 248 and 3.95 ± 3.16 ng·mL, respectively, occurring 22.5 ± 11 minutes after injection.",Transversus Abdominal Plane Block in Children: Efficacy and Safety: A Randomized Clinical Study and Pharmacokinetic Profile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094793/),ml·ng,3.95,14600,DB01002,Levobupivacaine
,27417947,absorption half-life,Epinephrine prolonged the levobupivacaine absorption half-life {4.22 [95 % confidence interval (CI) 2.53-6.50] vs. 7.02 [95 % CI 3.74-14.1]; p < 0.05} and reduced its relative bioavailability (0.84; 95 % CI 0.72-0.97; p < 0.05) The derived model predicts that levobupivacaine dose schemes should be halved from 3 mg kg(-1) body weight with epinephrine to 1.5 mg kg(-1) without epinephrine to obtain a comparable risk of anaesthetic toxicity symptoms of approximately 0.1 %.,Levobupivacaine absorption pharmacokinetics with and without epinephrine during TAP block: analysis of doses based on the associated risk of local anaesthetic toxicity. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27417947/),,4.22,21818,DB01002,Levobupivacaine
,27417947,absorption half-life,Epinephrine prolonged the levobupivacaine absorption half-life {4.22 [95 % confidence interval (CI) 2.53-6.50] vs. 7.02 [95 % CI 3.74-14.1]; p < 0.05} and reduced its relative bioavailability (0.84; 95 % CI 0.72-0.97; p < 0.05) The derived model predicts that levobupivacaine dose schemes should be halved from 3 mg kg(-1) body weight with epinephrine to 1.5 mg kg(-1) without epinephrine to obtain a comparable risk of anaesthetic toxicity symptoms of approximately 0.1 %.,Levobupivacaine absorption pharmacokinetics with and without epinephrine during TAP block: analysis of doses based on the associated risk of local anaesthetic toxicity. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27417947/),,7.02,21819,DB01002,Levobupivacaine
,27417947,relative bioavailability,Epinephrine prolonged the levobupivacaine absorption half-life {4.22 [95 % confidence interval (CI) 2.53-6.50] vs. 7.02 [95 % CI 3.74-14.1]; p < 0.05} and reduced its relative bioavailability (0.84; 95 % CI 0.72-0.97; p < 0.05) The derived model predicts that levobupivacaine dose schemes should be halved from 3 mg kg(-1) body weight with epinephrine to 1.5 mg kg(-1) without epinephrine to obtain a comparable risk of anaesthetic toxicity symptoms of approximately 0.1 %.,Levobupivacaine absorption pharmacokinetics with and without epinephrine during TAP block: analysis of doses based on the associated risk of local anaesthetic toxicity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27417947/),,0.,21820,DB01002,Levobupivacaine
,30447167,serum concentration,The observed median total levobupivacaine serum concentration was 0.30 mg/L (range: 0.20-0.70 mg/L) at 1 hour after the loading dose of 2 mg/kg.,A study of the dosage and duration for levobupivacaine infusion by the caudal-epidural route in infants aged 3-6 months. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30447167/),[mg] / [l],0.30,31316,DB01002,Levobupivacaine
,30447167,total levobupivacaine concentration,"The median total levobupivacaine concentration after 47 hours of infusion, at 0.2 mg/kg/h, was 1.21 mg/L (0.07-1.85 mg/L).",A study of the dosage and duration for levobupivacaine infusion by the caudal-epidural route in infants aged 3-6 months. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30447167/),[mg] / [l],1.21,31317,DB01002,Levobupivacaine
,14722171,Time to peak plasma concentration (T(max)),Time to peak plasma concentration (T(max)) ranged between 5 and 60 min (median 30 min) and was reached later in children aged less than 3 months (P<0.005).,Pharmacokinetics of levobupivacaine 0.25% following caudal administration in children under 2 years of age. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722171/),min,30,34250,DB01002,Levobupivacaine
,14722171,Peak plasma concentration (C(max)),"Peak plasma concentration (C(max)) ranged between 0.41 and 2.12 micro g ml(-1) (median 0.80, mean (SD) 0.91 (0.40) micro g ml(-1)).",Pharmacokinetics of levobupivacaine 0.25% following caudal administration in children under 2 years of age. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722171/),[μg] / [ml],0.80,34251,DB01002,Levobupivacaine
,14722171,Peak plasma concentration (C(max)),"Peak plasma concentration (C(max)) ranged between 0.41 and 2.12 micro g ml(-1) (median 0.80, mean (SD) 0.91 (0.40) micro g ml(-1)).",Pharmacokinetics of levobupivacaine 0.25% following caudal administration in children under 2 years of age. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722171/),[μg] / [ml],0.91,34252,DB01002,Levobupivacaine
,18761239,maximal concentrations,Mean +/- SD of maximal concentrations of levobupivacaine was 0.58 +/- 0.41 mg/L in group superficial and 0.52 +/- 0.28 mg/L in group combined (P = 0.71).,Pharmacokinetics of levobupivacaine 0.5% after superficial or combined (deep and superficial) cervical plexus block in patients undergoing minimally invasive parathyroidectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761239/),[mg] / [l],0.58,37998,DB01002,Levobupivacaine
,18761239,maximal concentrations,Mean +/- SD of maximal concentrations of levobupivacaine was 0.58 +/- 0.41 mg/L in group superficial and 0.52 +/- 0.28 mg/L in group combined (P = 0.71).,Pharmacokinetics of levobupivacaine 0.5% after superficial or combined (deep and superficial) cervical plexus block in patients undergoing minimally invasive parathyroidectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761239/),[mg] / [l],0.52,37999,DB01002,Levobupivacaine
,18761239,time required to reach the maximal concentrations,The median (range) time required to reach the maximal concentrations was 30 minutes (20-30 min) in group superficial and 20 minutes (15-30 min) in group combined (P = 0.45).,Pharmacokinetics of levobupivacaine 0.5% after superficial or combined (deep and superficial) cervical plexus block in patients undergoing minimally invasive parathyroidectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761239/),min,30,38000,DB01002,Levobupivacaine
,18761239,time required to reach the maximal concentrations,The median (range) time required to reach the maximal concentrations was 30 minutes (20-30 min) in group superficial and 20 minutes (15-30 min) in group combined (P = 0.45).,Pharmacokinetics of levobupivacaine 0.5% after superficial or combined (deep and superficial) cervical plexus block in patients undergoing minimally invasive parathyroidectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761239/),min,20,38001,DB01002,Levobupivacaine
,30032887,volume of distribution,Levobupivacaine volume of distribution after Caesarean section was higher than in healthy volunteers [172 L (70 kg)-1 (95% confidence interval: 137-207) vs 94.3 L (70 kg)-1 (95% CI: 62-128); P<0.01].,Pharmacokinetics of levobupivacaine with epinephrine in transversus abdominis plane block for postoperative analgesia after Caesarean section. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032887/),l,172,42369,DB01002,Levobupivacaine
,30032887,volume of distribution,Levobupivacaine volume of distribution after Caesarean section was higher than in healthy volunteers [172 L (70 kg)-1 (95% confidence interval: 137-207) vs 94.3 L (70 kg)-1 (95% CI: 62-128); P<0.01].,Pharmacokinetics of levobupivacaine with epinephrine in transversus abdominis plane block for postoperative analgesia after Caesarean section. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032887/),1/[kg],94.3,42370,DB01002,Levobupivacaine
,32397344,Plasma concentrations,Plasma concentrations were similar 30 min after application-0.389 mg × L-1 in the epidural and 0.318 mg × L-1 in the subpleural group (p = 0.33) and lower in the subpleural group at 120 min (p = 0.03).,A Randomized Comparison of Plasma Levobupivacaine Concentrations Following Thoracic Epidural Analgesia and Subpleural Paravertebral Analgesia in Open Thoracic Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32397344/),[mg] / [l],0.389,44360,DB01002,Levobupivacaine
,32397344,Plasma concentrations,Plasma concentrations were similar 30 min after application-0.389 mg × L-1 in the epidural and 0.318 mg × L-1 in the subpleural group (p = 0.33) and lower in the subpleural group at 120 min (p = 0.03).,A Randomized Comparison of Plasma Levobupivacaine Concentrations Following Thoracic Epidural Analgesia and Subpleural Paravertebral Analgesia in Open Thoracic Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32397344/),l-·mg,0.318,44361,DB01002,Levobupivacaine
,32397344,time to reach maximum plasma level,The time to reach maximum plasma level was similar in both groups-27.6 vs. 24.2 min.,A Randomized Comparison of Plasma Levobupivacaine Concentrations Following Thoracic Epidural Analgesia and Subpleural Paravertebral Analgesia in Open Thoracic Surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32397344/),min,27.6,44362,DB01002,Levobupivacaine
,32397344,time to reach maximum plasma level,The time to reach maximum plasma level was similar in both groups-27.6 vs. 24.2 min.,A Randomized Comparison of Plasma Levobupivacaine Concentrations Following Thoracic Epidural Analgesia and Subpleural Paravertebral Analgesia in Open Thoracic Surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32397344/),min,24.2,44363,DB01002,Levobupivacaine
,26982080,half-life,"As is shown in pharmacokinetic parameters, the half-life of LBP injection (2.7 h) was shorter than that of LBP in situ gels (23.9 h), suggesting that LBP injection was taken up by other tissues more rapidly than gels.",Preparation and investigation of a novel levobupivacaine in situ implant gel for prolonged local anesthetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26982080/),h,2.7,55946,DB01002,Levobupivacaine
,26982080,half-life,"As is shown in pharmacokinetic parameters, the half-life of LBP injection (2.7 h) was shorter than that of LBP in situ gels (23.9 h), suggesting that LBP injection was taken up by other tissues more rapidly than gels.",Preparation and investigation of a novel levobupivacaine in situ implant gel for prolonged local anesthetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26982080/),h,23.9,55947,DB01002,Levobupivacaine
,25188774,half-life,"Clonidine levels could be demonstrated during the 24-h postoperative period, with an average half-life of 22 h.",Clonidine as an adjuvant to prolong local analgesia in conventional scleral buckle surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25188774/),h,22,69632,DB01002,Levobupivacaine
,33386432,time to reach maximum plasma concentration,"In either of experiments, the time to reach maximum plasma concentration of levobupivacaine was shorter in the IP group than in the SC group (IP: 2 [2-5] min; SC: 5 [2-10] min; P = 0.04), and the maximum concentration of levobupivacaine did not differ between the IP and SC groups (IP: 0.45 [0.05-0.67] µg/mL; SC: 0.47 [0.21-0.62] µg/mL; P = 0.90).",Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),min,2,73226,DB01002,Levobupivacaine
,33386432,time to reach maximum plasma concentration,"In either of experiments, the time to reach maximum plasma concentration of levobupivacaine was shorter in the IP group than in the SC group (IP: 2 [2-5] min; SC: 5 [2-10] min; P = 0.04), and the maximum concentration of levobupivacaine did not differ between the IP and SC groups (IP: 0.45 [0.05-0.67] µg/mL; SC: 0.47 [0.21-0.62] µg/mL; P = 0.90).",Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),min,5,73227,DB01002,Levobupivacaine
,33386432,maximum concentration,"In either of experiments, the time to reach maximum plasma concentration of levobupivacaine was shorter in the IP group than in the SC group (IP: 2 [2-5] min; SC: 5 [2-10] min; P = 0.04), and the maximum concentration of levobupivacaine did not differ between the IP and SC groups (IP: 0.45 [0.05-0.67] µg/mL; SC: 0.47 [0.21-0.62] µg/mL; P = 0.90).",Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),[μg] / [ml],0.45,73228,DB01002,Levobupivacaine
,33386432,maximum concentration,"In either of experiments, the time to reach maximum plasma concentration of levobupivacaine was shorter in the IP group than in the SC group (IP: 2 [2-5] min; SC: 5 [2-10] min; P = 0.04), and the maximum concentration of levobupivacaine did not differ between the IP and SC groups (IP: 0.45 [0.05-0.67] µg/mL; SC: 0.47 [0.21-0.62] µg/mL; P = 0.90).",Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),[μg] / [ml],0.47,73229,DB01002,Levobupivacaine
,33386432,area under the curve from time 0 to 120 min,The area under the curve from time 0 to 120 min after levobupivacaine administration was significantly higher in the SC group than in the IP group in both experiments (IP: 0.29 [0.10-0.54] mg h/L; SC: 0.78 [0.39-0.98] mg h/L; P = 0.04).,Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),[h·mg] / [l],0.29,73230,DB01002,Levobupivacaine
,33386432,area under the curve from time 0 to 120 min,The area under the curve from time 0 to 120 min after levobupivacaine administration was significantly higher in the SC group than in the IP group in both experiments (IP: 0.29 [0.10-0.54] mg h/L; SC: 0.78 [0.39-0.98] mg h/L; P = 0.04).,Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),[h·mg] / [l],0.78,73231,DB01002,Levobupivacaine
exceed,33386432,Tmax,"On the other hand, when levobupivacaine is given subcutaneously, Tmax can exceed 1 h, so we need to be aware of local anesthetic toxicity during this period.",Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),h,1,73232,DB01002,Levobupivacaine
,31633607,Cmax,"From the pharmacokinetic parameters obtained, median Cmax, tmax,, and area under the concentration versus time curve were 0.315 mg/L, 17 minutes, and 41 mg/L·min, respectively.",Population Pharmacokinetics of Levobupivacaine During Transversus Abdominis Plane Block in Children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31633607/),[mg] / [l],0.315,79878,DB01002,Levobupivacaine
,31633607,tmax,"From the pharmacokinetic parameters obtained, median Cmax, tmax,, and area under the concentration versus time curve were 0.315 mg/L, 17 minutes, and 41 mg/L·min, respectively.",Population Pharmacokinetics of Levobupivacaine During Transversus Abdominis Plane Block in Children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31633607/),min,17,79879,DB01002,Levobupivacaine
,31633607,area under the concentration versus time curve,"From the pharmacokinetic parameters obtained, median Cmax, tmax,, and area under the concentration versus time curve were 0.315 mg/L, 17 minutes, and 41 mg/L·min, respectively.",Population Pharmacokinetics of Levobupivacaine During Transversus Abdominis Plane Block in Children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31633607/),[mg] / [l·min],41,79880,DB01002,Levobupivacaine
,10360857,maximum concentrations,"The maximum concentrations were 1.017 and 1.053 microg/ml, and the areas were 4.082 and 3.765 h(microg/ml) for the levobupivacaine and bupivacaine groups, respectively.",Clinical effects and maternal and fetal plasma concentrations of 0.5% epidural levobupivacaine versus bupivacaine for cesarean delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360857/),[μg] / [ml],1.017,99171,DB01002,Levobupivacaine
,10360857,maximum concentrations,"The maximum concentrations were 1.017 and 1.053 microg/ml, and the areas were 4.082 and 3.765 h(microg/ml) for the levobupivacaine and bupivacaine groups, respectively.",Clinical effects and maternal and fetal plasma concentrations of 0.5% epidural levobupivacaine versus bupivacaine for cesarean delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360857/),[μg] / [ml],1.053,99172,DB01002,Levobupivacaine
,10360857,areas,"The maximum concentrations were 1.017 and 1.053 microg/ml, and the areas were 4.082 and 3.765 h(microg/ml) for the levobupivacaine and bupivacaine groups, respectively.",Clinical effects and maternal and fetal plasma concentrations of 0.5% epidural levobupivacaine versus bupivacaine for cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360857/),[h(μg] / [ml],4.082,99173,DB01002,Levobupivacaine
,10360857,areas,"The maximum concentrations were 1.017 and 1.053 microg/ml, and the areas were 4.082 and 3.765 h(microg/ml) for the levobupivacaine and bupivacaine groups, respectively.",Clinical effects and maternal and fetal plasma concentrations of 0.5% epidural levobupivacaine versus bupivacaine for cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360857/),[h(μg] / [ml],3.765,99174,DB01002,Levobupivacaine
,10360857,Um,Umbilical vein-to-maternal vein ratios were 0.303 for the levobupivacaine group and 0.254 for the bupivacaine group.,Clinical effects and maternal and fetal plasma concentrations of 0.5% epidural levobupivacaine versus bupivacaine for cesarean delivery. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360857/),,0.303,99175,DB01002,Levobupivacaine
,10360857,Um,Umbilical vein-to-maternal vein ratios were 0.303 for the levobupivacaine group and 0.254 for the bupivacaine group.,Clinical effects and maternal and fetal plasma concentrations of 0.5% epidural levobupivacaine versus bupivacaine for cesarean delivery. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360857/),,0.254,99176,DB01002,Levobupivacaine
,29923955,Total,"Total and free maximum plasma levobupivacaine concentrations were lower in the lipid group than in control subjects (865 ± 98 vs 1145 ± 177 μg/L and 56.8 ± 7.5 vs 78.2 ± 13.7 μg/L, respectively; P < 0.01).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),[μg] / [l],865,100387,DB01002,Levobupivacaine
,29923955,Total,"Total and free maximum plasma levobupivacaine concentrations were lower in the lipid group than in control subjects (865 ± 98 vs 1145 ± 177 μg/L and 56.8 ± 7.5 vs 78.2 ± 13.7 μg/L, respectively; P < 0.01).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),[μg] / [l],1145,100388,DB01002,Levobupivacaine
,29923955,free maximum plasma levobupivacaine,"Total and free maximum plasma levobupivacaine concentrations were lower in the lipid group than in control subjects (865 ± 98 vs 1145 ± 177 μg/L and 56.8 ± 7.5 vs 78.2 ± 13.7 μg/L, respectively; P < 0.01).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),[μg] / [l],56.8,100389,DB01002,Levobupivacaine
,29923955,concentrations,"Total and free maximum plasma levobupivacaine concentrations were lower in the lipid group than in control subjects (865 ± 98 vs 1145 ± 177 μg/L and 56.8 ± 7.5 vs 78.2 ± 13.7 μg/L, respectively; P < 0.01).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),[μg] / [l],1145,100390,DB01002,Levobupivacaine
,29923955,concentrations,"Total and free maximum plasma levobupivacaine concentrations were lower in the lipid group than in control subjects (865 ± 98 vs 1145 ± 177 μg/L and 56.8 ± 7.5 vs 78.2 ± 13.7 μg/L, respectively; P < 0.01).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),[μg] / [l],56.8,100391,DB01002,Levobupivacaine
,29923955,concentrations,"Total and free maximum plasma levobupivacaine concentrations were lower in the lipid group than in control subjects (865 ± 98 vs 1145 ± 177 μg/L and 56.8 ± 7.5 vs 78.2 ± 13.7 μg/L, respectively; P < 0.01).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),[μg] / [l],78.2,100392,DB01002,Levobupivacaine
,29923955,Apparent volume of distribution,"Apparent volume of distribution and clearance were higher in the lipid group than in control subjects (211 ± 35 vs 170 ± 21 L and 35.1 ± 8.0 vs 25.8 ± 2.6 L/h, respectively; P < 0.05).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),l,211,100393,DB01002,Levobupivacaine
,29923955,Apparent volume of distribution,"Apparent volume of distribution and clearance were higher in the lipid group than in control subjects (211 ± 35 vs 170 ± 21 L and 35.1 ± 8.0 vs 25.8 ± 2.6 L/h, respectively; P < 0.05).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),l,170,100394,DB01002,Levobupivacaine
,29923955,clearance,"Apparent volume of distribution and clearance were higher in the lipid group than in control subjects (211 ± 35 vs 170 ± 21 L and 35.1 ± 8.0 vs 25.8 ± 2.6 L/h, respectively; P < 0.05).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),l,170,100395,DB01002,Levobupivacaine
,29923955,clearance,"Apparent volume of distribution and clearance were higher in the lipid group than in control subjects (211 ± 35 vs 170 ± 21 L and 35.1 ± 8.0 vs 25.8 ± 2.6 L/h, respectively; P < 0.05).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),[l] / [h],35.1,100396,DB01002,Levobupivacaine
,29923955,clearance,"Apparent volume of distribution and clearance were higher in the lipid group than in control subjects (211 ± 35 vs 170 ± 21 L and 35.1 ± 8.0 vs 25.8 ± 2.6 L/h, respectively; P < 0.05).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),[l] / [h],25.8,100397,DB01002,Levobupivacaine
,15321929,fraction absorbed (F(1)),"The fraction absorbed (F(1)) was 0.07 (95% CI: 0.02-013) smaller and the absorption half-life (t(1/2,a1)), characterizing the initial fast absorption phase, 3.6 min (95% CI: 0.8-6.4) shorter in the oldest group compared with the youngest group.",Effect of age on the clinical profile and systemic absorption and disposition of levobupivacaine after epidural administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15321929/),,0.07,102575,DB01002,Levobupivacaine
,15321929,"absorption half-life (t(1/2,a1))","The fraction absorbed (F(1)) was 0.07 (95% CI: 0.02-013) smaller and the absorption half-life (t(1/2,a1)), characterizing the initial fast absorption phase, 3.6 min (95% CI: 0.8-6.4) shorter in the oldest group compared with the youngest group.",Effect of age on the clinical profile and systemic absorption and disposition of levobupivacaine after epidural administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15321929/),min,3.6,102576,DB01002,Levobupivacaine
,18806025,Cmax,Median (range) levobupivacaine Cmax and Tmax measured were 1.48 (0.62-2.40) microg/mL and 37 (10-60) min.,Pharmacokinetics of levobupivacaine (2.5 mg/kg) after caudal administration in children younger than 3 years. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806025/),[μg] / [ml],1.48,106980,DB01002,Levobupivacaine
,18806025,Tmax,Median (range) levobupivacaine Cmax and Tmax measured were 1.48 (0.62-2.40) microg/mL and 37 (10-60) min.,Pharmacokinetics of levobupivacaine (2.5 mg/kg) after caudal administration in children younger than 3 years. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806025/),min,37,106981,DB01002,Levobupivacaine
,24953218,milk/plasma ratios,The milk/plasma ratios were 0.34±0.13 for levobupivacaine and 0.37±0.14 for bupivacaine.,Evaluation of levobupivacaine passage to breast milk following epidural anesthesia for cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24953218/),,0.34,134973,DB01002,Levobupivacaine
,24953218,milk/plasma ratios,The milk/plasma ratios were 0.34±0.13 for levobupivacaine and 0.37±0.14 for bupivacaine.,Evaluation of levobupivacaine passage to breast milk following epidural anesthesia for cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24953218/),,0.37,134974,DB01002,Levobupivacaine
,26945692,maximum plasma concentration (Cmax),The mean maximum plasma concentration (Cmax) and mean time to reach Cmax (Tmax) as determined by non-linear regression analysis were 1.05 μg.,A comparison of plasma levobupivacaine concentrations following transversus abdominis plane block and rectus sheath block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26945692/),μg,1.05,146295,DB01002,Levobupivacaine
,20600721,area under curve (AUC),"For brain pharmacokinetics, the CsA pretreatment raised significantly the area under curve (AUC) of BU (24.0+/-5.9 vs. 14.6+/-4.4min microg/mL, p=0.015).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[min·μg] / [ml],24.0,157122,DB01002,Levobupivacaine
,20600721,area under curve (AUC),"For brain pharmacokinetics, the CsA pretreatment raised significantly the area under curve (AUC) of BU (24.0+/-5.9 vs. 14.6+/-4.4min microg/mL, p=0.015).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[min·μg] / [ml],14.6,157123,DB01002,Levobupivacaine
,20600721,AUC,"For bile pharmacokinetics, LB and BU went through hepatobiliary excretion, and the AUC of BU was significantly higher than that of the LB group (6.6+/-1.0 vs. 4.6+/-0.6min microg/mL, p=0.005).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[min·μg] / [ml],6.6,157124,DB01002,Levobupivacaine
,20600721,AUC,"For bile pharmacokinetics, LB and BU went through hepatobiliary excretion, and the AUC of BU was significantly higher than that of the LB group (6.6+/-1.0 vs. 4.6+/-0.6min microg/mL, p=0.005).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[min·μg] / [ml],4.6,157125,DB01002,Levobupivacaine
,20600721,AUC,"In addition, the pretreatment of CsA significantly reduced the hepatobiliary excretion of BU in terms of AUC (4.4+/-0.8 vs. 6.6+/-1.0minmicrog/mL, p=0.003).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[minμg] / [ml],4.4,157126,DB01002,Levobupivacaine
,20600721,AUC,"In addition, the pretreatment of CsA significantly reduced the hepatobiliary excretion of BU in terms of AUC (4.4+/-0.8 vs. 6.6+/-1.0minmicrog/mL, p=0.003).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[minμg] / [ml],6.6,157127,DB01002,Levobupivacaine
,20600721,maximum concentration (C(max)),"Furthermore, the maximum concentration (C(max)) of BU diminished significantly as a result of the CsA pretreatment (0.10+/-0.03 vs. 0.20+/-0.05microg/mL, p=0.002).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[μg] / [ml],0.10,157128,DB01002,Levobupivacaine
,20600721,maximum concentration (C(max)),"Furthermore, the maximum concentration (C(max)) of BU diminished significantly as a result of the CsA pretreatment (0.10+/-0.03 vs. 0.20+/-0.05microg/mL, p=0.002).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[μg] / [ml],0.20,157129,DB01002,Levobupivacaine
,17131890,area under the curve,"There were no differences in area under the curve (1,551 +/- 387, 1,176 +/- 154 ng x hr x ml(-1)) and elimination half life (100 +/- 54, 78 +/- 37 min) between the two groups.",[Plasma levobupivacaine concentrations following epidural administration of levobupivacaine conjugated with or without maltosyl-beta-cyclodextrin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17131890/),[h·ng] / [ml],"1,551",159662,DB01002,Levobupivacaine
,17131890,area under the curve,"There were no differences in area under the curve (1,551 +/- 387, 1,176 +/- 154 ng x hr x ml(-1)) and elimination half life (100 +/- 54, 78 +/- 37 min) between the two groups.",[Plasma levobupivacaine concentrations following epidural administration of levobupivacaine conjugated with or without maltosyl-beta-cyclodextrin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17131890/),[h·ng] / [ml],"1,176",159663,DB01002,Levobupivacaine
,17131890,elimination half life,"There were no differences in area under the curve (1,551 +/- 387, 1,176 +/- 154 ng x hr x ml(-1)) and elimination half life (100 +/- 54, 78 +/- 37 min) between the two groups.",[Plasma levobupivacaine concentrations following epidural administration of levobupivacaine conjugated with or without maltosyl-beta-cyclodextrin]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17131890/),min,100,159664,DB01002,Levobupivacaine
,17131890,elimination half life,"There were no differences in area under the curve (1,551 +/- 387, 1,176 +/- 154 ng x hr x ml(-1)) and elimination half life (100 +/- 54, 78 +/- 37 min) between the two groups.",[Plasma levobupivacaine concentrations following epidural administration of levobupivacaine conjugated with or without maltosyl-beta-cyclodextrin]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17131890/),min,78,159665,DB01002,Levobupivacaine
,14576555,maximum,"The plasma concentration of levobupivacaine increased during the infusion period, reaching a maximum of 0.76 +/- 0.11 mug/ml in the 0.125% group and 0.48 +/- 0.12 mug/ml in the 0.0625% group by 24 h.","Efficacy, safety, and pharmacokinetics of levobupivacaine with and without fentanyl after continuous epidural infusion in children: a multicenter trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576555/),[μg] / [ml],0.76,170597,DB01002,Levobupivacaine
,14576555,maximum,"The plasma concentration of levobupivacaine increased during the infusion period, reaching a maximum of 0.76 +/- 0.11 mug/ml in the 0.125% group and 0.48 +/- 0.12 mug/ml in the 0.0625% group by 24 h.","Efficacy, safety, and pharmacokinetics of levobupivacaine with and without fentanyl after continuous epidural infusion in children: a multicenter trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576555/),[μg] / [ml],0.48,170598,DB01002,Levobupivacaine
,14576555,maximum concentration,"The plasma concentration of fentanyl also increased steadily, reaching a maximum concentration of 0.37 +/- 0.11 ng/ml by 24 h.","Efficacy, safety, and pharmacokinetics of levobupivacaine with and without fentanyl after continuous epidural infusion in children: a multicenter trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576555/),[ng] / [ml],0.37,170599,DB01002,Levobupivacaine
,23167288,Tabs,"While initial absorption was unchanged (Tabs 0.15 h 95%CI 0.12, 0.18 h), there was a late absorption peak characterized by a Tabs(LATE) 2.34 h (95%CI 1.44, 4.97 h).",Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),h,0.15,177557,DB01002,Levobupivacaine
,23167288,Tabs(LATE),"While initial absorption was unchanged (Tabs 0.15 h 95%CI 0.12, 0.18 h), there was a late absorption peak characterized by a Tabs(LATE) 2.34 h (95%CI 1.44, 4.97 h).",Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),h,2.34,177558,DB01002,Levobupivacaine
,23167288,volume of distribution,The population parameter estimate for volume of distribution was 157 l 70 kg(-1).,Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),[l] / [70·kg],157,177559,DB01002,Levobupivacaine
,23167288,Clearance,Clearance was 6.5 l · h(-1) 70 kg(-1) at 1-month PNA and increased with a maturation half-time of 1.6 months to reach 90% of the mature value (18.5 l · h(-1) 70 kg(-1)) by 5 months PNA.,Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),[l] / [70·h·kg],6.5,177560,DB01002,Levobupivacaine
,23167288,maturation half-time,Clearance was 6.5 l · h(-1) 70 kg(-1) at 1-month PNA and increased with a maturation half-time of 1.6 months to reach 90% of the mature value (18.5 l · h(-1) 70 kg(-1)) by 5 months PNA.,Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),month,1.6,177561,DB01002,Levobupivacaine
,23167288,maturation half-time,Clearance was 6.5 l · h(-1) 70 kg(-1) at 1-month PNA and increased with a maturation half-time of 1.6 months to reach 90% of the mature value (18.5 l · h(-1) 70 kg(-1)) by 5 months PNA.,Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),[l] / [70·h·kg],18.5,177562,DB01002,Levobupivacaine
,15248626,elimination half-life,"In surgical patients the elimination half-life (mean +/- SD: 196 +/- 65 min), total body clearanc (349 +/- 114 mL min(-1)) and volume of distribution at steady state (56 +/- 14 L), derived by compartmental analysis, were similar to those obtained by non-compartmental analysis.",The systemic absorption and disposition of levobupivacaine 0.5% after epidural administration in surgical patients: a stable-isotope study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248626/),min,196,187257,DB01002,Levobupivacaine
,15248626,total body clearanc,"In surgical patients the elimination half-life (mean +/- SD: 196 +/- 65 min), total body clearanc (349 +/- 114 mL min(-1)) and volume of distribution at steady state (56 +/- 14 L), derived by compartmental analysis, were similar to those obtained by non-compartmental analysis.",The systemic absorption and disposition of levobupivacaine 0.5% after epidural administration in surgical patients: a stable-isotope study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248626/),[ml] / [min],349,187258,DB01002,Levobupivacaine
,15248626,volume of distribution at steady state,"In surgical patients the elimination half-life (mean +/- SD: 196 +/- 65 min), total body clearanc (349 +/- 114 mL min(-1)) and volume of distribution at steady state (56 +/- 14 L), derived by compartmental analysis, were similar to those obtained by non-compartmental analysis.",The systemic absorption and disposition of levobupivacaine 0.5% after epidural administration in surgical patients: a stable-isotope study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248626/),l,56,187259,DB01002,Levobupivacaine
,15248626,fracti,"The fractio absorbed and half-life of the fast absorption process were 0.22 +/- 0.06 and 5.2 +/- 2.7 min, respectively.",The systemic absorption and disposition of levobupivacaine 0.5% after epidural administration in surgical patients: a stable-isotope study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248626/),min,0.22,187260,DB01002,Levobupivacaine
,15248626,half-life,"The fractio absorbed and half-life of the fast absorption process were 0.22 +/- 0.06 and 5.2 +/- 2.7 min, respectively.",The systemic absorption and disposition of levobupivacaine 0.5% after epidural administration in surgical patients: a stable-isotope study. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248626/),min,5.2,187261,DB01002,Levobupivacaine
,15248626,Th,"Th values for the slow absorption process were 0.84 +/- 0.14 and 386 +/- 91 min, respectively.",The systemic absorption and disposition of levobupivacaine 0.5% after epidural administration in surgical patients: a stable-isotope study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248626/),min,0.84,187262,DB01002,Levobupivacaine
,15248626,Th,"Th values for the slow absorption process were 0.84 +/- 0.14 and 386 +/- 91 min, respectively.",The systemic absorption and disposition of levobupivacaine 0.5% after epidural administration in surgical patients: a stable-isotope study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248626/),min,386,187263,DB01002,Levobupivacaine
,31806432,target plasma concentration (TPC),"Dogs were allocated to group fTCI [target plasma concentration (TPC) 1 ng mL-1] or group PNB (nerve stimulator-guided femoral-sciatic block using 0.2 and 0.1 mL kg-1 of levobupivacaine 0.5%, respectively).",Peripheral nerve block versus systemic analgesia in dogs undergoing tibial plateau levelling osteotomy: Analgesic efficacy and pharmacoeconomics comparison. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806432/),[ng] / [ml],1,190829,DB01002,Levobupivacaine
,30924096,Cmax,The median (interquartile range [IQR]) Cmax was 0.82 μg/mL (0.47-1.03).,Safety and Pharmacokinetics of Levobupivacaine Following Fascia Iliaca Compartment Block in Elderly Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924096/),[μg] / [ml],0.82,191511,DB01002,Levobupivacaine
,30924096,tmax,tmax was 45 min (41:20-60:00).,Safety and Pharmacokinetics of Levobupivacaine Following Fascia Iliaca Compartment Block in Elderly Patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924096/),min,45,191512,DB01002,Levobupivacaine
,31474859,maximum concentration,"The maximum concentration of QX-OH and levobupivacaine were 727.22 ± 43.38 µg/g and 256.02 ± 28.52 µg/g in muscle, 634.26 ± 36.04 µg/g and 429.63 ± 48.64 µg/g in sciatic nerve, and 711.71 ± 25.14 ng/ml and 114.40 ± 10.19 ng/ml in plasma, respectively.","The Preclinical Pharmacological Study of a Novel Long-Acting Local Anesthetic, a Fixed-Dose Combination of QX-OH/Levobupivacaine, in Rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31474859/),[μg] / [g],727.22,197206,DB01002,Levobupivacaine
,31474859,maximum concentration,"The maximum concentration of QX-OH and levobupivacaine were 727.22 ± 43.38 µg/g and 256.02 ± 28.52 µg/g in muscle, 634.26 ± 36.04 µg/g and 429.63 ± 48.64 µg/g in sciatic nerve, and 711.71 ± 25.14 ng/ml and 114.40 ± 10.19 ng/ml in plasma, respectively.","The Preclinical Pharmacological Study of a Novel Long-Acting Local Anesthetic, a Fixed-Dose Combination of QX-OH/Levobupivacaine, in Rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31474859/),[μg] / [g],256.02,197207,DB01002,Levobupivacaine
,31474859,maximum concentration,"The maximum concentration of QX-OH and levobupivacaine were 727.22 ± 43.38 µg/g and 256.02 ± 28.52 µg/g in muscle, 634.26 ± 36.04 µg/g and 429.63 ± 48.64 µg/g in sciatic nerve, and 711.71 ± 25.14 ng/ml and 114.40 ± 10.19 ng/ml in plasma, respectively.","The Preclinical Pharmacological Study of a Novel Long-Acting Local Anesthetic, a Fixed-Dose Combination of QX-OH/Levobupivacaine, in Rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31474859/),[μg] / [g],634.26,197208,DB01002,Levobupivacaine
,31474859,maximum concentration,"The maximum concentration of QX-OH and levobupivacaine were 727.22 ± 43.38 µg/g and 256.02 ± 28.52 µg/g in muscle, 634.26 ± 36.04 µg/g and 429.63 ± 48.64 µg/g in sciatic nerve, and 711.71 ± 25.14 ng/ml and 114.40 ± 10.19 ng/ml in plasma, respectively.","The Preclinical Pharmacological Study of a Novel Long-Acting Local Anesthetic, a Fixed-Dose Combination of QX-OH/Levobupivacaine, in Rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31474859/),[μg] / [g],429.63,197209,DB01002,Levobupivacaine
,31474859,maximum concentration,"The maximum concentration of QX-OH and levobupivacaine were 727.22 ± 43.38 µg/g and 256.02 ± 28.52 µg/g in muscle, 634.26 ± 36.04 µg/g and 429.63 ± 48.64 µg/g in sciatic nerve, and 711.71 ± 25.14 ng/ml and 114.40 ± 10.19 ng/ml in plasma, respectively.","The Preclinical Pharmacological Study of a Novel Long-Acting Local Anesthetic, a Fixed-Dose Combination of QX-OH/Levobupivacaine, in Rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31474859/),[ng] / [ml],711.71,197210,DB01002,Levobupivacaine
,31474859,maximum concentration,"The maximum concentration of QX-OH and levobupivacaine were 727.22 ± 43.38 µg/g and 256.02 ± 28.52 µg/g in muscle, 634.26 ± 36.04 µg/g and 429.63 ± 48.64 µg/g in sciatic nerve, and 711.71 ± 25.14 ng/ml and 114.40 ± 10.19 ng/ml in plasma, respectively.","The Preclinical Pharmacological Study of a Novel Long-Acting Local Anesthetic, a Fixed-Dose Combination of QX-OH/Levobupivacaine, in Rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31474859/),[ng] / [ml],114.40,197211,DB01002,Levobupivacaine
,31474859,absorption,"The absorption of QX-OH into circulation was very rapid at 0.71 ± 0.06 h, which was faster than that of levobupivacaine (4.11 ± 0.39 h, p = 0.003).","The Preclinical Pharmacological Study of a Novel Long-Acting Local Anesthetic, a Fixed-Dose Combination of QX-OH/Levobupivacaine, in Rats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31474859/),h,0,197212,DB01002,Levobupivacaine
,31474859,absorption,"The absorption of QX-OH into circulation was very rapid at 0.71 ± 0.06 h, which was faster than that of levobupivacaine (4.11 ± 0.39 h, p = 0.003).","The Preclinical Pharmacological Study of a Novel Long-Acting Local Anesthetic, a Fixed-Dose Combination of QX-OH/Levobupivacaine, in Rats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31474859/),h,4.11,197213,DB01002,Levobupivacaine
,31474859,half-time,"The half-time of QX-OH in plasma and local tissues had no significant difference (p = 0.329), with the values of 2.64 h, 3.20 h, and 3.79 h in plasma, muscle, and sciatic nerve, respectively.","The Preclinical Pharmacological Study of a Novel Long-Acting Local Anesthetic, a Fixed-Dose Combination of QX-OH/Levobupivacaine, in Rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31474859/),h,2.64,197214,DB01002,Levobupivacaine
,31474859,half-time,"The half-time of QX-OH in plasma and local tissues had no significant difference (p = 0.329), with the values of 2.64 h, 3.20 h, and 3.79 h in plasma, muscle, and sciatic nerve, respectively.","The Preclinical Pharmacological Study of a Novel Long-Acting Local Anesthetic, a Fixed-Dose Combination of QX-OH/Levobupivacaine, in Rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31474859/),h,3.20,197215,DB01002,Levobupivacaine
,31474859,half-time,"The half-time of QX-OH in plasma and local tissues had no significant difference (p = 0.329), with the values of 2.64 h, 3.20 h, and 3.79 h in plasma, muscle, and sciatic nerve, respectively.","The Preclinical Pharmacological Study of a Novel Long-Acting Local Anesthetic, a Fixed-Dose Combination of QX-OH/Levobupivacaine, in Rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31474859/),h,3.79,197216,DB01002,Levobupivacaine
,31474859,Tmax,"When levobupivacaine was used alone, the Tmax in plasma was 1.07 ± 0.16 h.","The Preclinical Pharmacological Study of a Novel Long-Acting Local Anesthetic, a Fixed-Dose Combination of QX-OH/Levobupivacaine, in Rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31474859/),h,1.07,197217,DB01002,Levobupivacaine
,31474859,Tmax,"Interestingly, the Tmax of levobupivacaine in the plasma was increased by four times in combination with QX-OH (4.11 ± 0.39 h).","The Preclinical Pharmacological Study of a Novel Long-Acting Local Anesthetic, a Fixed-Dose Combination of QX-OH/Levobupivacaine, in Rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31474859/),h,4.11,197218,DB01002,Levobupivacaine
,23038415,maximum arterial levobupivacaine concentrations,"The mean maximum arterial levobupivacaine concentrations with epinephrine were 0.36 (95% bootstrap confidence interval [95% CI], 0.30-0.42) μg/mL and 0.63 (95% CI, 0.49-0.85) μg/mL without epinephrine (P = 0.014, difference in means of 0.27 [95% CI, 0.12-0.46]).",Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038415/),[μg] / [ml],0.36,206873,DB01002,Levobupivacaine
,23038415,maximum arterial levobupivacaine concentrations,"The mean maximum arterial levobupivacaine concentrations with epinephrine were 0.36 (95% bootstrap confidence interval [95% CI], 0.30-0.42) μg/mL and 0.63 (95% CI, 0.49-0.85) μg/mL without epinephrine (P = 0.014, difference in means of 0.27 [95% CI, 0.12-0.46]).",Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038415/),[μg] / [ml],0.63,206874,DB01002,Levobupivacaine
,23038415,maximal venous levobupivacaine concentration,"The mean maximal venous levobupivacaine concentration was 0.32 (95% CI, 0.28-0.39) μg/mL and 0.49 (95% CI, 0.37-0.68) μg/mL, with and without epinephrine, respectively (P = 0.006, difference in means of 0.17 [95% CI, 0.08-0.33]).",Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038415/),[μg] / [ml],0.32,206875,DB01002,Levobupivacaine
,23038415,maximal venous levobupivacaine concentration,"The mean maximal venous levobupivacaine concentration was 0.32 (95% CI, 0.28-0.39) μg/mL and 0.49 (95% CI, 0.37-0.68) μg/mL, with and without epinephrine, respectively (P = 0.006, difference in means of 0.17 [95% CI, 0.08-0.33]).",Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038415/),[μg] / [ml],0.49,206876,DB01002,Levobupivacaine
,23038415,duration of the blockade,"The mean duration of the blockade was 10.2 hours (95% CI, 8.5-12.5 hours) with epinephrine and 10.3 hours (95% CI, 8.7-12.4 hours) without epinephrine (P = 1.000).",Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038415/),h,10.2,206877,DB01002,Levobupivacaine
,23038415,duration of the blockade,"The mean duration of the blockade was 10.2 hours (95% CI, 8.5-12.5 hours) with epinephrine and 10.3 hours (95% CI, 8.7-12.4 hours) without epinephrine (P = 1.000).",Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038415/),h,10.3,206878,DB01002,Levobupivacaine
,33683791,mature,A one-compartment model with a mature clearance 21.5 L h-1 70 kg-1 (CV 47.3%) and central volume 189 L 70 kg-1 (CV 37%) adequately described time-concentration profiles.,Prediction of levobupivacaine concentrations in neonates and infants following neuraxial rescue blocks. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683791/),[l] / [70·h·kg],21.5,217522,DB01002,Levobupivacaine
,33683791,clearance,A one-compartment model with a mature clearance 21.5 L h-1 70 kg-1 (CV 47.3%) and central volume 189 L 70 kg-1 (CV 37%) adequately described time-concentration profiles.,Prediction of levobupivacaine concentrations in neonates and infants following neuraxial rescue blocks. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683791/),[l] / [70·h·kg],21.5,217523,DB01002,Levobupivacaine
,33683791,central volume,A one-compartment model with a mature clearance 21.5 L h-1 70 kg-1 (CV 47.3%) and central volume 189 L 70 kg-1 (CV 37%) adequately described time-concentration profiles.,Prediction of levobupivacaine concentrations in neonates and infants following neuraxial rescue blocks. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683791/),[l] / [70·kg],189,217524,DB01002,Levobupivacaine
,33683791,maturation half-time,Clearance maturation was described using a maturation half-time of 11.5 weeks postnatal age.,Prediction of levobupivacaine concentrations in neonates and infants following neuraxial rescue blocks. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683791/),weeks,11.5,217525,DB01002,Levobupivacaine
,33683791,absorption half-time,The absorption half-time for spinal levobupivacaine was 2.6 min (CV 56.8%).,Prediction of levobupivacaine concentrations in neonates and infants following neuraxial rescue blocks. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683791/),min,2.6,217526,DB01002,Levobupivacaine
,33683791,peak concentrations,"The upper (97.5% prediction) for peak concentrations after rescue caudal levobupivacaine were 1.5 mg kg-1 , 2 mg kg-1 , and 2.5 mg kg-1 was 2.05 mg L-1 , 2.5 mg L-1 , and 2.9 mg L-1 respectively.",Prediction of levobupivacaine concentrations in neonates and infants following neuraxial rescue blocks. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683791/),[mg] / [l],2.05,217527,DB01002,Levobupivacaine
,33683791,peak concentrations,"The upper (97.5% prediction) for peak concentrations after rescue caudal levobupivacaine were 1.5 mg kg-1 , 2 mg kg-1 , and 2.5 mg kg-1 was 2.05 mg L-1 , 2.5 mg L-1 , and 2.9 mg L-1 respectively.",Prediction of levobupivacaine concentrations in neonates and infants following neuraxial rescue blocks. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683791/),[mg] / [l],2.5,217528,DB01002,Levobupivacaine
,33683791,peak concentrations,"The upper (97.5% prediction) for peak concentrations after rescue caudal levobupivacaine were 1.5 mg kg-1 , 2 mg kg-1 , and 2.5 mg kg-1 was 2.05 mg L-1 , 2.5 mg L-1 , and 2.9 mg L-1 respectively.",Prediction of levobupivacaine concentrations in neonates and infants following neuraxial rescue blocks. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683791/),[mg] / [l],2.9,217529,DB01002,Levobupivacaine
,10960398,fatal dose,The estimated fatal dose (mean +/- SD) was 277 +/- 51 mg for levobupivacaine (compared with 156 +/- 31 mg found previously for bupivacaine).,Tolerability of large-dose intravenous levobupivacaine in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10960398/),mg,277,220389,DB01002,Levobupivacaine
,10960398,fatal dose,The estimated fatal dose (mean +/- SD) was 277 +/- 51 mg for levobupivacaine (compared with 156 +/- 31 mg found previously for bupivacaine).,Tolerability of large-dose intravenous levobupivacaine in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10960398/),mg,156,220390,DB01002,Levobupivacaine
,10960398,initial,"Pharmacokinetic analysis indicated initial and total distribution volumes = 4.5 (+/-1.6) and 97 (+/-22) L, total clearance = 1.7 (+/-0.4) L/min, and slow half life = 70 (+/-29) min; these values did not differ from those found previously with smaller doses.",Tolerability of large-dose intravenous levobupivacaine in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10960398/),l,4.5,220391,DB01002,Levobupivacaine
,10960398,total distribution volumes,"Pharmacokinetic analysis indicated initial and total distribution volumes = 4.5 (+/-1.6) and 97 (+/-22) L, total clearance = 1.7 (+/-0.4) L/min, and slow half life = 70 (+/-29) min; these values did not differ from those found previously with smaller doses.",Tolerability of large-dose intravenous levobupivacaine in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10960398/),l,4.5,220392,DB01002,Levobupivacaine
,10960398,total distribution volumes,"Pharmacokinetic analysis indicated initial and total distribution volumes = 4.5 (+/-1.6) and 97 (+/-22) L, total clearance = 1.7 (+/-0.4) L/min, and slow half life = 70 (+/-29) min; these values did not differ from those found previously with smaller doses.",Tolerability of large-dose intravenous levobupivacaine in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10960398/),l,97,220393,DB01002,Levobupivacaine
,10960398,total clearance,"Pharmacokinetic analysis indicated initial and total distribution volumes = 4.5 (+/-1.6) and 97 (+/-22) L, total clearance = 1.7 (+/-0.4) L/min, and slow half life = 70 (+/-29) min; these values did not differ from those found previously with smaller doses.",Tolerability of large-dose intravenous levobupivacaine in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10960398/),[l] / [min],1.7,220394,DB01002,Levobupivacaine
,10960398,half life,"Pharmacokinetic analysis indicated initial and total distribution volumes = 4.5 (+/-1.6) and 97 (+/-22) L, total clearance = 1.7 (+/-0.4) L/min, and slow half life = 70 (+/-29) min; these values did not differ from those found previously with smaller doses.",Tolerability of large-dose intravenous levobupivacaine in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10960398/),min,70,220395,DB01002,Levobupivacaine
,16100236,clearance (CLt),"Population parameter estimates (between-subject variability) for total levobupivacaine were clearance (CLt) 12.8 [coefficient of variation (CV) 50.6%] litre h(-1) 70 kg(-1), volume of distribution (Vt) 202 (CV 31.6%) litre 70 kg(-1), absorption half-life (Tabs) 0.323 (CV 18.6%) h 70 kg(-1).",Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100236/),[l] / [70·h·kg],12.8,224439,DB01002,Levobupivacaine
,16100236,volume of distribution (Vt),"Population parameter estimates (between-subject variability) for total levobupivacaine were clearance (CLt) 12.8 [coefficient of variation (CV) 50.6%] litre h(-1) 70 kg(-1), volume of distribution (Vt) 202 (CV 31.6%) litre 70 kg(-1), absorption half-life (Tabs) 0.323 (CV 18.6%) h 70 kg(-1).",Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100236/),[l] / [70·kg],202,224440,DB01002,Levobupivacaine
,16100236,absorption half-life (Tabs),"Population parameter estimates (between-subject variability) for total levobupivacaine were clearance (CLt) 12.8 [coefficient of variation (CV) 50.6%] litre h(-1) 70 kg(-1), volume of distribution (Vt) 202 (CV 31.6%) litre 70 kg(-1), absorption half-life (Tabs) 0.323 (CV 18.6%) h 70 kg(-1).",Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100236/),[h] / [70·kg],0.323,224441,DB01002,Levobupivacaine
,16100236,clearance (CLfree),"Estimates for the unbound drug were clearance (CLfree) 104 (CV 43.5%) litre h(-1) 70 kg(-1), volume of distribution (Vfree) 1700 (CV 44.9%) litre 70 kg(-1), absorption half-life (Tabsfree) 0.175 (CV 83.7%) h 70 kg(-1).",Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100236/),[l] / [70·h·kg],104,224442,DB01002,Levobupivacaine
,16100236,volume of distribution (Vfree),"Estimates for the unbound drug were clearance (CLfree) 104 (CV 43.5%) litre h(-1) 70 kg(-1), volume of distribution (Vfree) 1700 (CV 44.9%) litre 70 kg(-1), absorption half-life (Tabsfree) 0.175 (CV 83.7%) h 70 kg(-1).",Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100236/),[l] / [70·kg],1700,224443,DB01002,Levobupivacaine
,16100236,absorption half-life (Tabsfree),"Estimates for the unbound drug were clearance (CLfree) 104 (CV 43.5%) litre h(-1) 70 kg(-1), volume of distribution (Vfree) 1700 (CV 44.9%) litre 70 kg(-1), absorption half-life (Tabsfree) 0.175 (CV 83.7%) h 70 kg(-1).",Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100236/),[h] / [70·kg],0.175,224444,DB01002,Levobupivacaine
,16100236,Time to peak plasma concentration (Tmax),There was no effect attributable to PNA on CL or V. Time to peak plasma concentration (Tmax) was 0.82 (CV 18%) h.,Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100236/),h,0.82,224445,DB01002,Levobupivacaine
,16100236,Peak plasma concentration (Cmax),Peak plasma concentration (Cmax) was 0.69 (CV 25%) microg ml(-1) for total levobupivacaine and 0.09 (CV 37%) microg ml(-1) for unbound levobupivacaine.,Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100236/),[μg] / [ml],0.69,224446,DB01002,Levobupivacaine
,16100236,Peak plasma concentration (Cmax),Peak plasma concentration (Cmax) was 0.69 (CV 25%) microg ml(-1) for total levobupivacaine and 0.09 (CV 37%) microg ml(-1) for unbound levobupivacaine.,Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100236/),[μg] / [ml],0.09,224447,DB01002,Levobupivacaine
,27061607,total venous levobupivacaine plasma concentrations,The median (IQR) total venous levobupivacaine plasma concentrations was 0.33 (0.25-0.42) μg·ml(-1) and unbound venous levobupivacaine was 19.5 (14.5-38) ng·ml(-1) . Median protein binding was 93.5 (91.4-96%).,Pharmacokinetics of levobupivacaine following infant spinal anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27061607/),[μg] / [ml],0.33,225806,DB01002,Levobupivacaine
,27061607,unbound venous levobupivacaine,The median (IQR) total venous levobupivacaine plasma concentrations was 0.33 (0.25-0.42) μg·ml(-1) and unbound venous levobupivacaine was 19.5 (14.5-38) ng·ml(-1) . Median protein binding was 93.5 (91.4-96%).,Pharmacokinetics of levobupivacaine following infant spinal anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27061607/),[ng] / [ml],19.5,225807,DB01002,Levobupivacaine
,27061607,protein binding,The median (IQR) total venous levobupivacaine plasma concentrations was 0.33 (0.25-0.42) μg·ml(-1) and unbound venous levobupivacaine was 19.5 (14.5-38) ng·ml(-1) . Median protein binding was 93.5 (91.4-96%).,Pharmacokinetics of levobupivacaine following infant spinal anesthesia. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27061607/),,93.5,225808,DB01002,Levobupivacaine
,12088972,time to sensory block,"The median time to sensory block was 12.5 min and 12.9 min, and mean duration of the block was 19 h and 22 h in normal versus ESRD patients, respectively.",Levobupivacaine for axillary brachial plexus block: a pharmacokinetic and clinical comparison in patients with normal renal function or renal disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088972/),min,12.5,225855,DB01002,Levobupivacaine
,12088972,time to sensory block,"The median time to sensory block was 12.5 min and 12.9 min, and mean duration of the block was 19 h and 22 h in normal versus ESRD patients, respectively.",Levobupivacaine for axillary brachial plexus block: a pharmacokinetic and clinical comparison in patients with normal renal function or renal disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088972/),min,12.9,225856,DB01002,Levobupivacaine
,12088972,duration of the,"The median time to sensory block was 12.5 min and 12.9 min, and mean duration of the block was 19 h and 22 h in normal versus ESRD patients, respectively.",Levobupivacaine for axillary brachial plexus block: a pharmacokinetic and clinical comparison in patients with normal renal function or renal disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088972/),h,19,225857,DB01002,Levobupivacaine
,12088972,duration of the,"The median time to sensory block was 12.5 min and 12.9 min, and mean duration of the block was 19 h and 22 h in normal versus ESRD patients, respectively.",Levobupivacaine for axillary brachial plexus block: a pharmacokinetic and clinical comparison in patients with normal renal function or renal disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088972/),h,22,225858,DB01002,Levobupivacaine
,12088972,peak concentration (C(max)),"mL(-1)) of 11 and 13, peak concentration (C(max)) (microg/mL) of 1.2 and 1.6, and a time to peak concentration (T(max)) (min) of 55 and 48, respectively.",Levobupivacaine for axillary brachial plexus block: a pharmacokinetic and clinical comparison in patients with normal renal function or renal disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088972/),[μg] / [ml],1.2,225859,DB01002,Levobupivacaine
,12088972,peak concentration (C(max)),"mL(-1)) of 11 and 13, peak concentration (C(max)) (microg/mL) of 1.2 and 1.6, and a time to peak concentration (T(max)) (min) of 55 and 48, respectively.",Levobupivacaine for axillary brachial plexus block: a pharmacokinetic and clinical comparison in patients with normal renal function or renal disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088972/),[μg] / [ml],1.6,225860,DB01002,Levobupivacaine
,12088972,time to peak concentration (T(max)),"mL(-1)) of 11 and 13, peak concentration (C(max)) (microg/mL) of 1.2 and 1.6, and a time to peak concentration (T(max)) (min) of 55 and 48, respectively.",Levobupivacaine for axillary brachial plexus block: a pharmacokinetic and clinical comparison in patients with normal renal function or renal disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088972/),min,55,225861,DB01002,Levobupivacaine
,12088972,time to peak concentration (T(max)),"mL(-1)) of 11 and 13, peak concentration (C(max)) (microg/mL) of 1.2 and 1.6, and a time to peak concentration (T(max)) (min) of 55 and 48, respectively.",Levobupivacaine for axillary brachial plexus block: a pharmacokinetic and clinical comparison in patients with normal renal function or renal disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088972/),min,48,225862,DB01002,Levobupivacaine
,16490091,volume of distribution (V),The population parameter estimate for volume of distribution (V) was 189 l.70 kg(-1).,Age and size are the major covariates for prediction of levobupivacaine clearance in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490091/),[l] / [70·kg],189,229641,DB01002,Levobupivacaine
,16490091,Clearance (CL),Clearance (CL) was 5.8 l.h(-1).70 kg(-1) at 1-month PNA and increased with a maturation half-time of 2.3 months to reach 80% of the mature value (22.1 l.h(-1).70 kg(-1)) by 6-month PNA.,Age and size are the major covariates for prediction of levobupivacaine clearance in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490091/),[l] / [70·h·kg],5.8,229642,DB01002,Levobupivacaine
,16490091,maturation half-time,Clearance (CL) was 5.8 l.h(-1).70 kg(-1) at 1-month PNA and increased with a maturation half-time of 2.3 months to reach 80% of the mature value (22.1 l.h(-1).70 kg(-1)) by 6-month PNA.,Age and size are the major covariates for prediction of levobupivacaine clearance in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490091/),month,2.3,229643,DB01002,Levobupivacaine
,16490091,maturation half-time,Clearance (CL) was 5.8 l.h(-1).70 kg(-1) at 1-month PNA and increased with a maturation half-time of 2.3 months to reach 80% of the mature value (22.1 l.h(-1).70 kg(-1)) by 6-month PNA.,Age and size are the major covariates for prediction of levobupivacaine clearance in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490091/),[l] / [70·h·kg],22.1,229644,DB01002,Levobupivacaine
,16490091,absorption half-time,The absorption half-time decreased from 0.36 h at 1-month PNA to 0.14 h (CV 48.1%) at 6-month PNA with a maturation half-time of 0.8 months.,Age and size are the major covariates for prediction of levobupivacaine clearance in children. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490091/),h,0.36,229645,DB01002,Levobupivacaine
,16490091,absorption half-time,The absorption half-time decreased from 0.36 h at 1-month PNA to 0.14 h (CV 48.1%) at 6-month PNA with a maturation half-time of 0.8 months.,Age and size are the major covariates for prediction of levobupivacaine clearance in children. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490091/),h,0.14,229646,DB01002,Levobupivacaine
,16490091,maturation half-time,The absorption half-time decreased from 0.36 h at 1-month PNA to 0.14 h (CV 48.1%) at 6-month PNA with a maturation half-time of 0.8 months.,Age and size are the major covariates for prediction of levobupivacaine clearance in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490091/),month,0.8,229647,DB01002,Levobupivacaine
,17350525,maximum plasma concentration (Cpmax),There was rapid absorption of levobupivacaine after bolus with mean (standard deviation) maximum plasma concentration (Cpmax) of 0.51(0.24) microg/mL in a median time to maximum concentration tCpmax of 15 minutes.,"Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[μg] / [ml],0.51,231928,DB01002,Levobupivacaine
,17350525,time to maximum concentration tCpmax,There was rapid absorption of levobupivacaine after bolus with mean (standard deviation) maximum plasma concentration (Cpmax) of 0.51(0.24) microg/mL in a median time to maximum concentration tCpmax of 15 minutes.,"Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),min,15,231929,DB01002,Levobupivacaine
,17350525,Cpmax,"Mean Cpmax fentanyl and clonidine after bolus were 0.62 (0.37) and 0.79 (0.23) ng/mL, in a median tCpmax of 15 and 22.5 minutes, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[ng] / [ml],0.62,231930,DB01002,Levobupivacaine
,17350525,Cpmax,"Mean Cpmax fentanyl and clonidine after bolus were 0.62 (0.37) and 0.79 (0.23) ng/mL, in a median tCpmax of 15 and 22.5 minutes, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[ng] / [ml],0.79,231931,DB01002,Levobupivacaine
,17350525,tCpmax,"Mean Cpmax fentanyl and clonidine after bolus were 0.62 (0.37) and 0.79 (0.23) ng/mL, in a median tCpmax of 15 and 22.5 minutes, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),min,15,231932,DB01002,Levobupivacaine
,17350525,tCpmax,"Mean Cpmax fentanyl and clonidine after bolus were 0.62 (0.37) and 0.79 (0.23) ng/mL, in a median tCpmax of 15 and 22.5 minutes, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),min,22.5,231933,DB01002,Levobupivacaine
,17350525,Cpmax,Mean Cpmax levobupivacaine after infusion was 0.47 (0.41) microg/mL in a median tCpmax of 24 hours.,"Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[μg] / [ml],0.47,231934,DB01002,Levobupivacaine
,17350525,tCpmax,Mean Cpmax levobupivacaine after infusion was 0.47 (0.41) microg/mL in a median tCpmax of 24 hours.,"Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),h,24,231935,DB01002,Levobupivacaine
,17350525,Cpmax,"There was progressive accumulation of fentanyl and clonidine at 24 hours with a mean Cpmax of 0.72 (0.33) and 1.74 (0.70) ng/mL, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[ng] / [ml],0.72,231936,DB01002,Levobupivacaine
,17350525,Cpmax,"There was progressive accumulation of fentanyl and clonidine at 24 hours with a mean Cpmax of 0.72 (0.33) and 1.74 (0.70) ng/mL, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[ng] / [ml],1.74,231937,DB01002,Levobupivacaine
